WO1999064001A3 - Methods and compositions for increasing penetration of hiv protease inhibitors - Google Patents

Methods and compositions for increasing penetration of hiv protease inhibitors Download PDF

Info

Publication number
WO1999064001A3
WO1999064001A3 PCT/EP1999/003827 EP9903827W WO9964001A3 WO 1999064001 A3 WO1999064001 A3 WO 1999064001A3 EP 9903827 W EP9903827 W EP 9903827W WO 9964001 A3 WO9964001 A3 WO 9964001A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
hiv protease
protease inhibitors
increasing penetration
Prior art date
Application number
PCT/EP1999/003827
Other languages
French (fr)
Other versions
WO1999064001A2 (en
Inventor
Kenneth Russell Brouwer
Joseph William Polli
Original Assignee
Glaxo Group Ltd
Kenneth Russell Brouwer
Joseph William Polli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Kenneth Russell Brouwer, Joseph William Polli filed Critical Glaxo Group Ltd
Priority to EP99927848A priority Critical patent/EP1094814A2/en
Priority to JP2000553070A priority patent/JP2002517443A/en
Priority to AU45051/99A priority patent/AU4505199A/en
Publication of WO1999064001A2 publication Critical patent/WO1999064001A2/en
Publication of WO1999064001A3 publication Critical patent/WO1999064001A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to methods for increasing penetration of HIV protease-inhibiting compounds into tissues expressing P-glycoprotein.
PCT/EP1999/003827 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of hiv protease inhibitors WO1999064001A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99927848A EP1094814A2 (en) 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of hiv protease inhibitors
JP2000553070A JP2002517443A (en) 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of HIV protease inhibitors
AU45051/99A AU4505199A (en) 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of hiv protease inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812189.0A GB9812189D0 (en) 1998-06-05 1998-06-05 Methods and compositions for increasing penetration of HIV protease inhibitors
GB9812189.0 1998-06-05

Publications (2)

Publication Number Publication Date
WO1999064001A2 WO1999064001A2 (en) 1999-12-16
WO1999064001A3 true WO1999064001A3 (en) 2000-02-03

Family

ID=10833305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003827 WO1999064001A2 (en) 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of hiv protease inhibitors

Country Status (5)

Country Link
EP (1) EP1094814A2 (en)
JP (1) JP2002517443A (en)
AU (1) AU4505199A (en)
GB (1) GB9812189D0 (en)
WO (1) WO1999064001A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
JP2000072749A (en) * 1998-08-24 2000-03-07 Mitsui Chemicals Inc Apoptosis-inducing agent using quinoline derivative
JP2000290181A (en) * 1999-04-01 2000-10-17 Mitsui Chemicals Inc Intracerebral migration potentiator for encephalopathy therapeutic agent
WO2002098849A2 (en) 2001-06-01 2002-12-12 Elan Pharmaceuticals, Inc. Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases
JP2004532894A (en) 2001-06-13 2004-10-28 イーラン　ファーマスーティカルズ、インコーポレイテッド Amine diol for treating Alzheimer's disease
WO2003006013A1 (en) 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Diaminediols for the treatment of alzheimer's disease
US7053109B2 (en) 2001-07-10 2006-05-30 Pharmacia & Upjohn Company Aminediols for the treatment of Alzheimer's disease
WO2003029169A2 (en) 2001-10-04 2003-04-10 Elan Pharmaceuticals, Inc. Hydroxypropylamines
WO2003050073A1 (en) 2001-12-06 2003-06-19 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
AU2003303141A1 (en) 2002-04-30 2004-07-22 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer's disease
TW200512195A (en) 2003-04-21 2005-04-01 Elan Pharm Inc Benzamide 2-hydroxy-3-diaminoalkanes
WO2005087751A2 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
JP2007533741A (en) 2004-04-22 2007-11-22 イーライ リリー アンド カンパニー BACE inhibitor
CA2573138A1 (en) 2004-07-09 2006-01-26 Elan Pharmaceuticals Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US20140275139A1 (en) * 2013-03-12 2014-09-18 Hiv Diagnostics, Inc. Mdr method and products for treating hiv/aids

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012132A1 (en) * 1991-01-11 1992-07-23 Laboratoires Glaxo S.A. Acridine derivatives
WO1997035587A1 (en) * 1996-03-22 1997-10-02 Glaxo Group Limited Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
WO1999012570A2 (en) * 1997-09-05 1999-03-18 Glaxo Group Limited Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012132A1 (en) * 1991-01-11 1992-07-23 Laboratoires Glaxo S.A. Acridine derivatives
WO1997035587A1 (en) * 1996-03-22 1997-10-02 Glaxo Group Limited Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
WO1999012570A2 (en) * 1997-09-05 1999-03-18 Glaxo Group Limited Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DREWE J., ET AL.: "HIV protease inhibitor Ritonavir: a more potent inhibitor of p_glycoprotein than the Cyclosporine analogue SDZ PSC 833", BIOCHEM. PHARMACOL., vol. 57, no. 10, 1999, pages 1147 - 1152, XP002114524 *
HYAFIL F ET AL: "IN VITRO AND IN VIVO REVERSAL OF MULTIDRUG RESISTANCE BY GF120918, AN ACRIDONECARBOXAMIDE DERIVATIVE", CANCER RESEARCH, vol. 53, no. 19, 1 October 1993 (1993-10-01), pages 4595 - 4602, XP000565696, ISSN: 0008-5472 *
KIM R.B. ET AL.: "The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors", J. CLINICAL INVESTIGATION, vol. 101, no. 2, 15 January 1998 (1998-01-15), pages 289 - 294, XP002114521 *
LEE C.G.L. ET AL.: "HIV-1 Protease inhibitors are substrates for the MDR1 multidrug transporter", BIOCHEMISTRY, vol. 37, no. 11, 1998, pages 3594 - 3601, XP002114522 *
WASHINGTON C.B. ET AL.: "Saquinavir is a hight affinity substrate for the multidrug transporter P-glycoprotein", CLIN. PHARMACOL. THERAP., vol. 61, no. 2, 1997, pages 193, XP002114523 *

Also Published As

Publication number Publication date
GB9812189D0 (en) 1998-08-05
EP1094814A2 (en) 2001-05-02
AU4505199A (en) 1999-12-30
WO1999064001A2 (en) 1999-12-16
JP2002517443A (en) 2002-06-18

Similar Documents

Publication Publication Date Title
WO1999064001A3 (en) Methods and compositions for increasing penetration of hiv protease inhibitors
AU2001276048A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
WO2004032713A3 (en) Sealants for skin and other tissues
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
AU2001241474A1 (en) Biosensor compositions and methods of use
AU2001233081A1 (en) Composition for treatment of stress
WO2003059296A3 (en) Compositions comprising collagen and metalloprotease inhibitors
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2001284690A1 (en) Compositions exhibiting synergistic inhibition of the expression and/or activityof cyclooxygenase-2
AU2001219651A1 (en) Mulch composition and method
AU2002224079A1 (en) O/W emulsion composition and method of preparing the same
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
WO2004021990A3 (en) Compositions and kits for the removal of irritating compounds from bodily surfaces
AU2001239363A1 (en) Method for fighting against arthropods destructive of crops and composition therefor
AU2002225894A1 (en) Methods and compositions for the control of coccidiosis
AU2001243347A1 (en) Hydratable form of keratin for use as a soil amendment
AU5694901A (en) Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission
AU2001245764A1 (en) Novel compounds and compositions as protease inhibitors
AU2001234782A1 (en) Compositions and methods for promoting healthy joints
AU2001271031A1 (en) Cosmetic compositions for reducing and method of using the same
AU2001274181A1 (en) Composition and method for biocide treatment of surfaces
WO2001091700A8 (en) Composition and method for enhancing elasticity of tissue
AU2001224021A1 (en) Compositions for protecting plants and method of using the same
AU2001280721A1 (en) Compositions of iodonium compounds and methods and uses thereof
AU2002215333A1 (en) Compositions for release of radiosensitizers, and methods of making and using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999927848

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09701949

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999927848

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999927848

Country of ref document: EP